Immune checkpoint blockade provokes resident memory T cells to eliminate head and neck cancer

Joshua R Veatch; Stanley R Riddell

doi:10.1016/j.cell.2022.07.006

Immune checkpoint blockade provokes resident memory T cells to eliminate head and neck cancer

Cell. 2022 Aug 4;185(16):2848-2849. doi: 10.1016/j.cell.2022.07.006.

Authors

Joshua R Veatch¹, Stanley R Riddell²

Affiliations

¹ Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
² Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Electronic address: [email protected].

PMID: 35931017
DOI: 10.1016/j.cell.2022.07.006

Abstract

Immune checkpoint blockade is effective in treating many human cancers. In this issue of Cell, Luoma et al. show that tissue-resident memory T cells in head and neck cancers rapidly respond to immune checkpoint blockade, and they identify specific CD8⁺ T cells in pretreatment blood that predict pathologic tumor regression.

Publication types

Comment

MeSH terms

CD8-Positive T-Lymphocytes*
Head and Neck Neoplasms* / drug therapy
Humans
Immune Checkpoint Inhibitors
Memory T Cells
Tumor Microenvironment

Substances

Immune Checkpoint Inhibitors